Factors impacting time to diagnosis in pediatric, adolescent and young adult (AYA) patients with solid tumors. Read more about Factors impacting time to diagnosis in pediatric, adolescent and young adult (AYA) patients with solid tumors.
Impact of low-income public insurance on survival for children and young adults with bone and soft tissue sarcomas. Read more about Impact of low-income public insurance on survival for children and young adults with bone and soft tissue sarcomas.
Prognostic factors among older adults with advanced non-small cell lung cancer (NSCLC): A multisite cohort study. Read more about Prognostic factors among older adults with advanced non-small cell lung cancer (NSCLC): A multisite cohort study.
Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia. Read more about Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
Disparities in lung cancer outcomes for veterans with comorbid mental disorders. Read more about Disparities in lung cancer outcomes for veterans with comorbid mental disorders.
Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance. Read more about Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.
Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Read more about Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer.
A multibiomarker approach to predict prostate cancer pathology outcomes. Read more about A multibiomarker approach to predict prostate cancer pathology outcomes.
Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO). Read more about Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma. Read more about Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
